The Risks of miRNA Therapeutics: In a Drug Target Perspective
Sign Up to like & getrecommendations! Published in 2021 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s288859
Abstract: Abstract RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs, were approved by the Food and Drug Administration in 2018 and 2019, respectively. However, there is rare news on the advance of miRNA… read more here.
Keywords: drug; mirna therapeutics; drug target; target perspective ... See more keywords